Refine by
Impact Assessment Articles & Analysis
31 news found
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is proud to announce the launch of its innovative Influenza A Virus Mouse Models to assess the impact of virus-host interactions. These mouse models can facilitate comprehensive research into the pathogenesis, immune response, and efficacy of antiviral ...
With a focus on conductive coatings, metal cabinets, conductive plastics, laminates/tapes/foils, and miscellaneous shielding methods across North America, Europe, and Asia-Pacific, the report meticulously identifies and assesses technologies impacting plastics and other materials. In addition, it elucidates trends in electronics, medical, automotive, and consumer ...
“The mechanism of action of ATG-037 in inhibiting adenosine-generating CD73 is expected to reverse an immunosuppressed tumor microenvironment, thereby creating potential additive benefit with multiple immuno-oncological approaches. We are very excited to assess the impact of ATG-037 as a monotherapy and in combination with MSD’s KEYTRUDA®, and ...
Healthbit has partnered with LSE – London School of Economics and Political Science, to launch a global initiative which aims to assess the impact of the COVID-19 lockdown on the lives of people, including students and staff. ...
The results evaluating the association of DCISionRT, a predictive DCIS Biosignature to assess the impact of Endocrine Therapy (ET) on 10-year ipsilateral breast recurrence (IBR) risk after breast conserving surgery alone or with radiation therapy (RT), will be presented on June 7, 2022 at McCormick Place, Chicago, IL. ...
The company will evaluate the safety and efficacy of VX-147 in a single pivotal clinical trial designed to assess the impact of VX-147, on top of standard of care, on kidney function and proteinuria in people with AMKD. ...
Regression tests evaluate design changes and assess their impact throughout the requirements, design, and verification stages. These design changes may be limited in scope—requiring only a handful of tests to be redone. As an alternative, they may impact enough of the design that it is necessary to re-execute the entire suite of tests. ...
OncoDNA, a genomic and theranostic company specializing in precision medicine, and Bergonié Institute, a non-profit private hospital entirely devoted to fighting cancer, today announced a new clinical trial to evaluate the use of comprehensive biomarker testing and liquid biopsy in 700 patients diagnosed with an advanced metastatic cancer. The Appolo study will recruit patients from 6 ...
Are you interested in serving on the IAIA Board? Current IAIA members are encouraged to self-nominate for a Board position for the 2022 election, to be held in January 2022 for the three-year term of May 2022 through May 2025. To self-nominate, an interested member should gather at least five signatures of support from other current IAIA members. Please see the Self-Nomination Instructions ...
Tune in Thursday, 18 November, at 15:00 GMT for the final (live!) session of the virtual forum "Think Big: A Cleaner, Greener COVID-19 Recovery,” hosted jointly by IAIA and the Earth Law Center. Moderator Peter Henderson of Reuters News will lead a live panel featuring several Think Big speakers. Listen as they bring together various aspects of their presentations to focus on the road ...
FDA granted Breakthrough Device Designation for Perimeter B-Series OCT coupled with ImgAssist AI, and Perimeter is conducting a randomized, multi-site, pivotal study to evaluate it against the current standard of care and assess the impact on re-operation rates for patients undergoing breast conservation surgery. ...
FDA granted Breakthrough Device Designation for Perimeter B-Series OCT coupled with ImgAssist AI, and Perimeter has plans to initiate a randomized, multi-site, pivotal study to evaluate it against the current standard of care and assess the impact on re-operation rates for patients undergoing breast conservation surgery. ...
According to a new survey from S&P Global Market Intelligence, almost all the businesses surveyed (90%) expressed some degree of optimism about their expectations for performance in 2021 as the economy recovers from the COVID-19 pandemic. This optimism comes alongside widespread reinvention in how many of these businesses will operate going forward. Conducted by 451 Research, the enterprise ...
FDA granted Breakthrough Device Designation for Perimeter B-Series OCT coupled with ImgAssist AI, and Perimeter has plans to initiate a randomized, multi-site, pivotal study to evaluate it against the current standard of care and assess the impact on re-operation rates for patients undergoing breast conservation surgery. ...
"The prevalence of T1D has grown dramatically over the past 60 years, so the results of this study could have an enormous impact on public health if the increasing incidence of T1D, and its physical, emotional and financial consequences, could be turned back," said Dr. ...
IAIA recently released the second of a series of surveys on how COVID-19 is affecting the policy and practice of impact assessment. The survey obtained the views of over 700 individuals involved in impact assessment across the globe. ...
This difficult decision was taken by the Board of Directors, IAIA21 organizers, and staff after careful consideration of the myriad of factors surrounding uncertainties created by the COVID pandemic. The health and safety of our attendees is still our highest priority. Although we are disappointed to not be meeting in Seville as we had previously hoped, we are excited for the new ...
Are you interested in serving on the IAIA Board? Current IAIA members are encouraged to self-nominate for a Board position for the 2021 election, to be held in January 2021 for the three-year term of May 2021 through May 2024. To self-nominate, an interested member should gather at least five signatures of support from other current IAIA members. Please see the Self-Nomination Instructions ...
IAIA members were recently able to study the results of the second survey on “Impact of COVID-19 on Impact Assessment,” which was done 29 July – 6 August 2020. This survey has resulted in some data that are troubling for the practice of impact assessment (IA), and may require a focused ...
The primary endpoint of the study will be the percentage of patients who are able to achieve target glycemic control (HbA1c less than or equal to 7%) without the need for insulin at 24 weeks post procedure, comparing Revita DMR to the sham arm. Secondary endpoints will assess the impact of Revita DMR on additional glycemic, hepatic, and cardiovascular endpoints. ...